Platelet activating factor antagonism with XXXX protects the kidney against @entity63 .

@entity8 @entity63 @entity1219 @entity1372 @entity3766 @entity35
The present study has been conducted to evaluate the eventual role of the platelet activating factor (PAF) in post-ischemic recovery of renal function, using @entity3766 , a PAF receptor antagonist, in the anesthetized @entity35 . In Groups 1 and 2, animals were maintained hydropenic (fractional excretion of @entity1372 less than 1%), while in Groups 3 and 4, studies were performed under extracellular expansion (0.9% @entity1219 , 5% of body weight), a procedure known to protect the kidney from @entity63 . Groups 1 and 3 (control animals) were untreated, whereas Groups 2 and 4 received an intravenous bolus of @entity3766 (3mg/kg), immediately before clearance studies. After three 20-minute control periods, the @entity8 was occluded during 30 minutes. Four consecutive 20-minute clearance periods were taken after the release of occlusion. In Groups 1 and 2, urine flow (UV) increased from 3.1 +/- 0.9 to 20.9 +/- 3.6 ml/min, and from 6.8 +/- 0.3 to 40.4 +/- 4.5 ml/min, respectively, from control to the last period of recovery. Glomerular filtration (GFR) recovered to 38% of control values, from 0.58 +/- 0.09 to 0.22 +/- 0.10 ml/min in Group 1, as opposed to Group 2, where GFR recovered to 69%, from 0.61 +/- 0.07 to 0.42 +/- 0.06 ml/min. Urinary @entity1372 (UNaV) increased from 0.3 +/- 0.1 to 3.0 +/- 0.9 microEq/min, and from 1.0 +/- 0.3 to 6.0 +/- 0.7 microEq/min, in Groups 1 and 3. UV rose from 14.3 +/- 2.5 to 35.3 +/- 3.5 microliters/min, and from 14.2 +/- 2.1 to 68.6 +/- 9.3 microliters/min, in Groups 3 and 4, during the same periods.(ABSTRACT TRUNCATED AT 250 WORDS)
